Stock comparison
JOHNSON & JOHNSON is 166.3x more valuable than Kiniksa Pharmaceuticals, Ltd. by market capitalization ($623.71 B vs $3.75 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
JNJ is larger
JOHNSON & JOHNSON is 166.3x more valuable than Kiniksa Pharmaceuticals, Ltd. by market capitalization ($623.71 B vs $3.75 B).
Market value leader
JNJ
JOHNSON & JOHNSON is 166.3x more valuable than Kiniksa Pharmaceuticals, Ltd. by market capitalization ($623.71 B vs $3.75 B).
Revenue leader
JNJ
KNSA: $677.56M vs JNJ: $94.19B.
Profit leader
JNJ
KNSA: $59.01M vs JNJ: $26.80B.
Margin leader
JNJ
KNSA: 8.7% vs JNJ: 28.5% net margin.
| Metric | KNSA | JNJ |
|---|---|---|
| Market cap | $3.75 B | $623.71 B |
| US-listed rank | #1658 | #17 |
| Revenue (latest FY) | $677.56M | $94.19B |
| Net income (latest FY) | $59.01M | $26.80B |
| Net margin | 8.7% | 28.5% |
| P/E (trailing FY) | 63.6x | 23.3x |
| SEC filings | 733 | 990 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
JOHNSON & JOHNSON is 166.3x more valuable than Kiniksa Pharmaceuticals, Ltd. by market capitalization ($623.71 B vs $3.75 B).
In their latest fiscal years, Kiniksa Pharmaceuticals, Ltd. reported $677.56M in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Kiniksa Pharmaceuticals, Ltd. and JOHNSON & JOHNSON, or browse the full rankings.